Treatment of hepatocellular carcinoma with long acting somatostatin analogues

Oncology Reports

Volumn 9, Issue 4, 2002, Pages 903-907

  Samonakis, Demetrios N ^a   Moschandreas, Joanna ^b   Arnaoutis, Theodora ^c   Skordilis, Panagiotis ^a   Leontidis, Christos ^a   Vafiades, Irene ^c   Kouroumalis, Elias ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Hepatocellular carcinoma; Lanreotide; Long acting somatostatin; Octreotide LAR

Indexed keywords

DRUG DERIVATIVE; SOMATOSTATIN; TUMOR MARKER;

AGED; ARTICLE; CANCER STAGING; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HUMAN; KARNOFSKY PERFORMANCE STATUS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TUMOR; MALE; METABOLISM; PATHOLOGY; PROGNOSIS; QUALITY OF LIFE; SURVIVAL RATE;

AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; KARNOFSKY PERFORMANCE STATUS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; NEOPLASM STAGING; PROGNOSIS; QUALITY OF LIFE; SOMATOSTATIN; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0036634556     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.4.903     Document Type: Article

References (27)

1. El Refaie A, Savage K, Bhattacharygas S, et al: HCV associated hepatocellular carcinoma without cirrhosis. J Hepatol 24: 277-285, 1996. (Pubitemid 26104883)
2. Rustgi VK: Epidemiology of hepatocellular carcinoma. Gastroenterol Clin North Am 16: 545-551, 1987.
3. Colombo M, De Francis R, Del Ninno E, et al: Hepatocellular carcinoma in Italian patients without cirrhosis. N Engl J Med 325: 675-680, 1991.
4. Bolondi L, Sofia S, Siringo S, et al: Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 48: 251-259, 2001. (Pubitemid 32141852)
5. Okuda K, Fujimoto I, Hanai A, et al: Changing incidence of hepatocellular carcinoma in lapan. Cancer Res 47: 4967-4972, 1987. (Pubitemid 17143048)
6. Hashem B, El-Serag and Masin AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340: 745-750, 1999.
7. Yamamoto J, Iwatsuki S, Kosuge T, et al: Should hepatomas be treated with hepatic resection or transplantation? Cancer 86: 1151-1158, 1999. (Pubitemid 29446996)
8. Michel S, Sue B, Montpeyroux F, et al: Liver resection or transplantation for hepatocellular carcinoma? Retrospective analysis of 215 patients with cirrhosis. J Hepatol: 1274-1280, 1997. (Pubitemid 27346640)
9. Philosophe B, Greig PD, Hemming AW, et al: Surgical management of hepatocellular carcinoma: resection or transplantation? J Gastrointest Surg 2: 21-27, 1998. (Pubitemid 128423460)
10. Kouroumalis EA, Skordilis PG, Moschandrea I, et al: Natural history of advanced hepatocellular carcinoma in Crete. Association with hepatitis C virus. Eur J Gastroenterol Hepatol 9: 981-988, 1997. (Pubitemid 27448068)
11. Simoneti RG, Liberati A, Angiolini C, et al: Treatment of HCC: a systematic review of randomised controlled trials. Ann Oncol 8: 117-136, 1997. (Pubitemid 27112878)
12. Raoul JL, Boucher E and Kebrat P: Non-surgical treatment of hepatocellular carcinoma. Bull Cancer 86: 537-543, 1999.
13. Liu CL, Fan ST, Ng FO, et al: Treatment of advanced HCC with tamoxifen and the correlation with expression of hormone receptors: a prospective randomised study. Am J Gastroenterol 95:218-222,2000.
14. Liovet JM, Sala M, Castells L, et al: Randomised controlled trial of IFN treatment for advanced HCC. Hepatology 31: 54-58, 2000. (Pubitemid 30033689)
15. Kouroumalis EA, Skordilis P, Thermos K, et al: Treatment of HCC with octreotide: a randomised controlled study. Gut 42: 442-447, 1998. (Pubitemid 28197039)
16. Raderer M, Hejna MH, Kurtaran A, et al: Successful treatment of an advanced hepatocellular carcinoma with long acting somatostatin analogue lanreotide. Am J Gastroenterol 94: 278-279, 1999. (Pubitemid 29063488)
17. Raderer M, Hejna MH, Muller C, et al: Treatment of hepatocellular cancer with the long acting somatostatin analogue lanreotide in vivo and in vitro. Int J Oncol 16: 1197-1201, 2000.
18. Allgaier HP, Becker G and Blum HE: A therapeutic study of hepatocellular carcinoma using octreotide (HECTOR). Dtsch Med Wochenschr 125: 320, 2000. (Pubitemid 30163429)
19. Okuda K, Ohtsuki T, Obata H, et al: Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Cancer 56:918-928, 1985. (Pubitemid 15228292)
20. Yates JW, Chalmer B and Mc Kegney FP: Evaluation of patients with advanced cancer using the Karnofsky performance status Cancer 45: 2220-2224, 1980. (Pubitemid 10150440)
21. Altman DG, De Stavola BL, Love SB and Stepniewska KA: Review of survival analyses published in cancer journals. Br J Cancer 72: 511-518, 1995.
22. Kaplan EL and Meier P: Non-parametric estimation for incomplete observation. J Am Stat Assoc 53: 457-481, 1958.
23. Pocock SJ: Clinical Trials: a Practical Approach. Wiley and Sons Ltd., New York, pp54-60, pp221-227, 1983.
24. Collett D: Modeling Survival Data in Medical Research. Chapman and Hall, London, pp54-57, 1994.
25. Altman DG and Andersen PK: Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 4: 319(7223), 1492-1495, 1999.
26. Pawarode A, Voravud N, Sriuranpong V, et al: Natural history of untreated primary hepatocellular carcinoma. Am J Clin Oncol 21: 386-391, 1998.
27. Reubi JC, Zimmermann A, Jones S, et al: Regulatory peptide receptors in human hepatocellular carcinoma. Gut 45: 766-774, 1999. (Pubitemid 29492155)